Bayer
FDA Approves Illumina Cancer Genomic Profiling Assay as CDx for Kinase Inhibitors From Bayer, Lilly
The test's first CDx approvals are for Bayer's Vitrakvi in solid tumors and for Lilly's Retevmo in non-small cell lung cancer.
Burning Rock, Bayer to Develop NGS-Based Companion Diagnostics in China
The companies will jointly develop next-generation sequencing-based companion diagnostic tests for Bayer's precision cancer therapies.
Top Five Articles on 360Dx Last Week: Siemens Healthineers Shutters PCR Business; More
Last week, readers were most interested in a story about Siemens Healthineers shutting down FTD, which it acquired in 2017.
Thermo Fisher Scientific, Bayer to Develop NGS-Based CDx for Precision Cancer Therapies
The companies plan to codevelop CDx assays for Bayer's cancer therapies using Thermo Fisher’s Oncomine Dx Express Test on the Ion Torrent Genexus Dx sequencing system.
Illumina Adds CDx Indication to European TruSight Oncology Test for NTRK Gene Fusion Detection
The CDx pan-cancer indication will allow the identification of patients with NTRK gene fusions who may benefit from therapy with Bayer's Vitrakvi (larotrectinib).